Disfunzione metabolica e l'uso di farmaci adiuvanti nella diabete di tipo 1.

PURPOSE OF REVIEW: Type 1 diabetes is increasingly complicated by obesity and broader metabolic dysfunction, yet there are barriers to the use of adjunctive pharmacotherapies in this population. This review evaluates the evidence for metformin, glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs), and sodium-glucose cotransporter-2 (SGLT2) inhibitors (SGLT2i) in type 1 diabetes, with a focus on weight loss, glycaemic control, insulin dose requirements and safety. RECENT FINDINGS: Despite advances, metformin remains the only adjunct widely endorsed in national guidelines for adults with type 1 diabetes. In clinical trials, GLP-1RAs used alongside automated insulin delivery systems de